HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells

Qingxue Li,1 Wei Bu,1 Erin Gabriel,2 Fiona Aguilar,1 Yo Hoshino,1 Hiroko Miyadera,3,4 Christoph Hess,5 Ronald L. Hornung,4 Amitava Roy,7 and Jeffrey I. Cohen1

1Medical Virology Section, Laboratory of Infectious Diseases, 2Division of Clinical Research, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA. 3Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 4Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan. 5Immunobiology Laboratory, Department of Biomedicine, and Medical Outpatient Division, University Hospital Basel, Basel, Switzerland. 6Clinical Services Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA. 7Bioinformatics and Computational Biosciences Branch, Rocky Mountain Laboratories, NIH, Hamilton, Montana, USA.

Introduction

Over 95% of adults are infected with Epstein-Barr virus (EBV) worldwide. Although the infection often presents with nonspecific or no symptoms in young children, EBV frequently causes infectious mononucleosis in young adults (1). EBV is associated with a number of malignancies, including Burkitt and Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric carcinoma. In immune-deficient patients EBV can result in lymphoproliferative disease.

The reservoir for EBV infection in humans is the B lymphocyte, which is the site of latent infection and virus persistence. The critical role for B cells in EBV infection is demonstrated by the observation that persons who lack mature B cells cannot be infected with EBV (2). EBV encodes numerous glycoproteins on its envelope that participate in virus entry into cells, including glycoproteins gp350, gB, gH/gL, and gp42 (3). The initial virus attachment onto B cells is mediated through gp350 binding to its cellular ligand CD21 (also known as CR2 or C3d receptor) or CD35 (also known as CR1) (4–6). A complex of 4 glycoproteins, gH/gL, gB, and gp42, is required for fusion of the viral envelope with the cell plasma membrane. EBV gp42 utilizes HLA class II molecules as a coreceptor to infect B cells (7, 8). EBV gp42, a type II membrane glycoprotein, interacts with gH/gL through its N-terminal domain. The C-terminus of gp42 bears a similarity with C-type lectin domains and is important for binding to the β chain of HLA class II (9, 10). Blocking the interaction between gp42 and HLA class II with antibodies against either of these proteins, or with soluble gp42 protein, impairs EBV infection of B cells (7).

HLA class II molecules are composed of 2 polypeptide chains (α and β). Each α and β chain has 2 domains — a highly conserved α2 and β2 region and a highly polymorphic α1 and β1 domain. The antigen-peptide-binding groove is positioned between domains α1 and β1 (11). HLA class II molecules are encoded...
by 3 different loci, HLA-DR, -DQ, and -DP, which share approximately 70% amino acid identity with each
other and are inherited as haplotypes. Previous studies have shown that all 3 HLA class II molecules, HLA-
DR, HLA-DQ, and HLA-DP, can serve as receptors for EBV gp42 (9, 12). While peptide antigen binding
to the peptide pocket of HLA class II involves both the α1 and β1 subunits of the αβ heterodimer, gp42
interacts only with the β1 subunit of HLA class II (9, 10, 13). Nevertheless, soluble gp42 inhibits antigen
presentation (9, 14, 15), possibly by blocking the interaction between the T cell receptor and the HLA–pep-
tide antigen complex (15).

About 5% of adults are seronegative for EBV throughout their lifetime. It is generally assumed that
selection for resistance to infection drives evolution of MHC variation (16). This seems paradoxical for
EBV, which has evolved to utilize HLA class II to facilitate entry and infection. Therefore, determining
which HLA-DQ alleles are associated with EBV infectivity or resistance to EBV infection is important
to better understand how the virus has evolved with MHC molecules. A previous study using transiently
expressed HLA-DQ in a human lymphoblastoid cell line (LCL) lacking HLA class II found that cells
expressing HLA-DQ2 (α*0501 × β*0201) were more susceptible to infection with a genetically modified
laboratory strain of EBV, while HLA-DQ3.3–expressing (α*0301 × β*03032) cells were resistant to infec-
tion, and suggested a coreceptor restriction within the HLA-DQ locus for EBV infection (17). However,
since the LCL used has a large homozygous deletion in the HLA class II and HLA-DM coding regions,
and is deficient in the assembly and transport of class I molecules to the cell surface, it is not clear if the
observed coreceptor restriction applies to cells without such mutations and to humans that are infected
with wild-type viruses. To address these questions, we identified 106 EBV-seronegative individuals from a
pool of about 3,300 healthy blood donors and performed genotyping for the HLA-DQ
β1 chain. Our results
indicate that HLA-DQ alleles influence EBV infectivity in naturally infected humans. Subsequent in vitro
binding and infectivity assays showed that the specificity of EBV gp42 for binding to specific HLA-DQ
alleles was sufficient to account for allele-specific correlations with EBV seropositivity and seronegativity
in naturally infected humans.

**Results**

The HLA-DQ β1 *02/*02 allele correlates with EBV seropositivity, while HLA-DQ β1 *04/*05, HLA-DQ β1
*06/*06, and DQ β1 *02/*03 correlate with EBV seronegativity. About 3,300 healthy adult blood donors were
recruited from the United States and Switzerland and 106 were identified as seronegative for EBV. In addition, 218 blood donors who had been part of the screening process to identify seronegative donors in
both countries, but were found to be EBV seropositive were randomly selected to serve as controls. Table 1
shows the ethnicity of the EBV-seronegative donors and the seropositive controls that were blindly selected
from the EBV-seropositive candidate pool. Consistent with prior reports (18–21), we observed that the
EBV-seronegative group had a higher percentage of subjects of European descent than African Americans
and other non-white individuals, compared with the EBV-seropositive group.

We determined HLA-DQ alleles for each of the 324 blood donors (Table 2). Three HLA-DQ β1 alleles
were associated with increased odds of EBV seronegativity, and 1 with decreased odds of EBV seronegativity.
All 4 subjects with DQ β1 *04/*05 were EBV seronegative (unadjusted Fisher exact P value = 0.011,
Table 3). There was a higher than expected proportion of subjects with DQ β1 *06/*06 and DQ β1 *02/*03 among the EBV-seronegative persons compared with the seropositive group (for DQ β1 *06/*06 odds ratio
2.62, unadjusted Fisher exact P value = 0.03; for DQ β1 *02/*03 odds ratio 1.79, P value = 0.087). All
12 persons with the DQ β1 *02/*02 genotype were EBV seropositive (unadjusted Fisher exact P value =
However, when the P values were adjusted for multiple comparisons considering all 15 DQ genotypes using false discovery rate adjustment they were no longer significant. This reflects the need for a larger sample size, since HLA-DQ is highly polymorphic and allele frequencies in the general population vary.

When we analyzed the data for an association between EBV serostatus and the expression of any single HLA-DQ β1 allele, we found that persons with at least one HLA-DQ β1 *03 allele had the highest observed odds of being seronegative (odds ratio 1.21). We also observed that there was a higher proportion of EBV-seropositive individuals who carried at least one DQ β1 *02 or one DQ β1 *04 allele (odds ratio 0.79 and 0.70, respectively); however, these associations did not reach statistical significance (Table 4).

**EBV** gp42 protein binds more efficiently to HLA-DQ β1 *02/*02–positive cells than to HLA-DQ β1 *03/*03–positive or *04/*05–positive cells. The major target of EBV infection in vivo is B cells, and EBV utilizes HLA

### Table 2. Frequency of the 15 combinations of the 2 HLA-DQ β1 alleles among EBV seronegative blood donors (top panel) and seropositive controls (bottom panel)

<table>
<thead>
<tr>
<th>β1 – 1st Alleles</th>
<th>β1 – 2nd Alleles</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>*02</td>
<td>*03</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>*02</td>
<td>*04</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>*03</td>
<td>*05</td>
<td>6</td>
<td>16</td>
</tr>
<tr>
<td>*04</td>
<td>*05</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>*05</td>
<td>*06</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>*06</td>
<td>–</td>
<td>–</td>
<td>13</td>
</tr>
</tbody>
</table>

### Table 3. Statistical analysis of HLA-DQ β1 genotype among EBV-seronegative and -seropositive blood donors

<table>
<thead>
<tr>
<th>Allele Frequency</th>
<th>DQ β1 Two Alleles</th>
<th>n</th>
<th>EBV-Seronegative Donors</th>
<th>EBV-Seropositive Controls</th>
<th>Statistical Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>*02/*02</td>
<td>12</td>
<td>0</td>
<td>0.00</td>
<td>12</td>
<td>5.50</td>
</tr>
<tr>
<td>*02/*03</td>
<td>45</td>
<td>20</td>
<td>18.87</td>
<td>25</td>
<td>11.47</td>
</tr>
<tr>
<td>*02/*04</td>
<td>9</td>
<td>2</td>
<td>1.89</td>
<td>7</td>
<td>3.21</td>
</tr>
<tr>
<td>*02/*05</td>
<td>32</td>
<td>10</td>
<td>9.43</td>
<td>22</td>
<td>10.09</td>
</tr>
<tr>
<td>*02/*06</td>
<td>24</td>
<td>4</td>
<td>3.77</td>
<td>20</td>
<td>9.17</td>
</tr>
<tr>
<td>*03/*03</td>
<td>39</td>
<td>14</td>
<td>13.21</td>
<td>25</td>
<td>11.47</td>
</tr>
<tr>
<td>*03/*04</td>
<td>4</td>
<td>0</td>
<td>0.00</td>
<td>4</td>
<td>1.83</td>
</tr>
<tr>
<td>*03/*05</td>
<td>24</td>
<td>6</td>
<td>5.66</td>
<td>18</td>
<td>8.26</td>
</tr>
<tr>
<td>*03/*06</td>
<td>49</td>
<td>16</td>
<td>15.09</td>
<td>33</td>
<td>15.14</td>
</tr>
<tr>
<td>*04/*04</td>
<td>2</td>
<td>0</td>
<td>0.00</td>
<td>2</td>
<td>0.92</td>
</tr>
<tr>
<td>*04/*05</td>
<td>4</td>
<td>4</td>
<td>3.77</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>*04/*06</td>
<td>8</td>
<td>1</td>
<td>0.94</td>
<td>7</td>
<td>3.21</td>
</tr>
<tr>
<td>*05/*05</td>
<td>8</td>
<td>3</td>
<td>2.83</td>
<td>5</td>
<td>2.29</td>
</tr>
<tr>
<td>*05/*06</td>
<td>40</td>
<td>13</td>
<td>12.26</td>
<td>27</td>
<td>12.39</td>
</tr>
<tr>
<td>*06/*06</td>
<td>24</td>
<td>13</td>
<td>12.26</td>
<td>11</td>
<td>5.05</td>
</tr>
</tbody>
</table>

FDR, false discovery rate. Bold indicates statistically significant for Fisher exact P value.
Table 4. Statistical analysis of HLA-DQ β1 allele frequency among EBV-seronegative and -seropositive blood donors

<table>
<thead>
<tr>
<th></th>
<th>Donors with at least 1 allele</th>
<th></th>
<th></th>
<th>Odds Ratio (Seronegative)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EBV Seronegative</td>
<td>EBV Seropositive</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>% of Seronegative</td>
<td>n</td>
<td>% of Seropositive</td>
</tr>
<tr>
<td>DQ β1 *02</td>
<td>36</td>
<td>34</td>
<td>86</td>
<td>39.5</td>
</tr>
<tr>
<td>DQ β1 *03</td>
<td>56</td>
<td>52.8</td>
<td>105</td>
<td>48.2</td>
</tr>
<tr>
<td>DQ β1 *04</td>
<td>7</td>
<td>6.6</td>
<td>20</td>
<td>9.2</td>
</tr>
<tr>
<td>DQ β1 *05</td>
<td>36</td>
<td>34</td>
<td>72</td>
<td>33</td>
</tr>
<tr>
<td>DQ β1 *06</td>
<td>47</td>
<td>44.3</td>
<td>98</td>
<td>45</td>
</tr>
</tbody>
</table>

EBV gp42 protein binds more efficiently to HLA-DQ β1 *02/*02–positive and *05/*05–positive cells than to HLA-DQ β1 *03/*03–positive and *06/*06–positive cells when expressed in the absence of other HLA molecules. In addition to HLA-DQ, EBV gp42 can also bind to DR and DP (7, 12). This may explain the variation in binding efficiency observed with cell lines that express identical DQ β1 alleles, such as IHW01021 and IHW01019 (Figure 2). In addition, although structural studies suggested that gp42 interacts with HLA β chain only (9, class II as a coreceptor for virus entry into B cells mediated by EBV gp42 binding to HLA class II molecules. To further investigate the contribution of HLA-DQ to EBV infectivity, we studied the ability of EBV gp42 to bind to different HLA-DQ alleles. LCLs with HLA-DQ β1 *02/*02 (IHW09086), DQ β1 *03/*03 (IHW09035), and DQ β1 *04/*05 (IHW01021 and IHW01019) (Table 5) were stained with anti–HLA-DQ antibody Ia3 and each expressed similar levels of the DQ protein on the cell surface (Figure 1). Jurkat cells (a T cell leukemia cell line), which do not express HLA-DQ on their surface (22), served as a negative control. Purified gp42-His was incubated on ice with the cells and binding was quantified using anti-His antibody and FACS. Cells expressing HLA-DQ β1 *02/*02 bound gp42 more efficiently than cells expressing DQ β1 *03/*03 or DQ β1 *04/*05 (unadjusted Wilcoxon signed-rank test P value = 0.03 for DQ β1 *02/*02 vs. *03/*03; P = 0.002 for DQ β1 *02/*02 vs. *04/*05; Figure 2). In contrast, no significant difference in gp42 binding between DQ β1 *03/*03 and DQ β1 *04/*05 was observed (Wilcoxon rank-sum test P value = 0.118 for either of the DQ β1 *04/*05 cell lines). While both DQ β1 *04/*05 cell lines bound less gp42 than the DQ β1 *02/*02 cell line, there was a consistent difference in binding between the two DQ β1 *04/*05 cell lines over multiple experiments, although the difference did not reach statistical significance (unadjusted Wilcoxon signed-rank P value = 0.06). Since the 2 cell lines have the identical genotypes for HLA-DQ α1/β1, -DP α1/β1, and -DR β1, this indicates that other genetic factors, such as HLA-DR β3, β4, and β5, likely affect binding of gp42.

We also tested gp42 binding using purified gp42-Fc, in which IgG1 Fc was fused to the N-terminus of gp42 (a type II membrane protein) (9). A previous study showed that gp42-Fc blocks EBV infection at the entry step (7). Unlike gp42-His, which is a monomer, gp42-Fc forms a dimer through its Fc domain. To minimize nonspecific binding mediated through cell surface Fc receptor (FcR), a construct with a mutant Fc coding sequence was used that has markedly diminished (>10,000-fold less) FcR binding activity (9), and an FcR blocking solution was added before incubation with anti-human IgG antibody to reduce background binding. To further control for the Fc domain fused to gp42, purified IgG-Fc protein was used as an internal control, and gp42 binding was calculated by subtraction of the background binding observed with the internal control. Similar to the results observed with gp42-His, binding of gp42-Fc to cells expressing DQ β1 *02/*02 was significantly increased as compared with cells expressing DQ β1 *03/*03 or DQ β1 *04/*05 (unadjusted Wilcoxon signed-rank test P value = 0.008 for DQ β1 *02/*02 vs. *03/*03; P = 0.002 for DQ β1 *02/*02 vs. *04/*05; Figure 3). In contrast, no significant difference was observed for gp42-Fc binding between DQ β1 *03/*03 and *04/*05 (unadjusted Wilcoxon signed-rank test P value = 0.2 for DQ β1 *03/*03 vs. *04/*05). The results of both the gp42-His and gp42-Fc binding experiments, showing that EBV gp42 has increased binding to cells expressing DQ β1 *02/*02 compared with cells expressing DQ β1 *03/*03 or DQ β1 *04/*05, are consistent with the associations of HLA-DQ β1 types with the EBV serostatus of blood donors. These data provide evidence of the importance of EBV gp42 binding to HLA-DQ as a predictor of EBV seronegativity.
10, 23), HLA α chains may be important, since the proper pairing of α and β subunits is important to maintain stability of HLA αβ heterodimers (24). Therefore, we constructed mouse cell lines stably expressing human HLA-DQ alleles, in the absence of other HLA proteins, and performed gp42 binding assays. Mouse 3T3 cells were transduced with retroviruses encoding various combinations of DQ α alleles (also expressing GFP) and DQ β alleles (also expressing a puromycin-resistance gene); cell lines expressing the DQ proteins were selected by their resistance to puromycin, and by FACS sorting for GFP-positive cells. The resulting cells were greater than 90% GFP positive. Cell surface DQ expression was measured by staining with anti-DQ Ia3. The resulting ratio of cell surface DQ expression to internal control GFP was designated as ΔMHC, which is a function of intrinsic stability of the DQ proteins, the combined outcome of αβ heterodimer assembly, transportation to the cell surface, and the rate of DQ protein turnover (24). HLA αβ heterodimer stability on the cell surface (ΔMHC) varied among different DQ αβ heterodimers (Table 6). To provide an interassay control, we normalized ΔMHC for each HLA-DQ αβ molecule against that of DQ α1*01:01/β1*06:02 (and therefore assigned the normalized ΔMHC for DQ α1*01:02/β1*06:02 as 1), since DQ α1*01:02/β1*06:02 has been reported to be highly stable, even in the presence of SDS (24, 25). In agreement with prior work, α1*01:01/β1*06:02 was the most stable DQ molecule in our study (Table 6). A previous study of DQ alleles in the general population showed high haplotype and phenotype frequencies for DQ α1*05:01/β1*02:01, α1*05:01/β1*03:01, α1*04:01/β1*04:02, α1*01:01/β1*05:01, and α1*01:01/β1*06:02 (26) (NCBI dbMHC database, https://www.ncbi.nlm.nih.gov/gv/mhc/). Therefore, we used cells stably expressing these DQ alleles for the gp42-His binding assay. gp42-His protein was incubated with cells and detected with anti-His mouse antibody. Surface DQ expression was quantified, ΔMHC was calculated, and gp42 binding efficiency was defined as the ratio of the mean fluorescence intensity of gp42 binding divided by ΔMHC. HLA-DQ β1*02:01 bound gp42 with higher efficiency than β1*03:01 (unadjusted Wilcoxon signed-rank P value < 0.001, Figure 4 and Table 7). HLA-DQ β1*06:02 bound gp42 with low efficiency, similar to that of β1*03:01 (unadjusted Wilcoxon signed-rank P value =0.353 for β1*03:01 vs. β1*06:02; P = 0.001 for β1*02:01 vs. β1*06:02) (Table 7). Taken together, these results are consistent with those obtained for gp42 binding to the human cell lines and our observations for EBV serostatus and HLA-DQ β1 types in blood donors.

HLA-DQ β1*02/*02 alleles facilitate EBV infectivity more efficiently than other alleles. In our cohort of healthy donors, all individuals with a DQ β1*02/*02 genotype were EBV seropositive (Table 3). To determine if the enhanced gp42 binding associated with DQ β1*02/*02 correlates with increased EBV infectivity, we cloned DQ α and β chains into vectors, expressed these genes in human cells, and verified that the mature DQ α1/β1 heterodimers were expressed on the cell surface (Li et al.,
We then expressed the DQα1/β1 heterodimers in a human LCL line, 721.174, and infected the cells with recombinant EBV (293-EBV) that encodes a hygromycin-resistance gene (27). 721.174 cells have a deletion in HLA-DQ, -DR, and part of -DP (28). EBV infectivity was measured by real-time RT-qPCR detecting the copy number of hygromycin-resistance gene mRNA normalized against the copy number of GAPDH mRNA amplified in the same reaction as an internal control. Expression of exogenous DQβ1 *02/*02 significantly enhanced EBV infection compared with *03/*03 (Wilcoxon signed-rank P value = 0.03) (Figure 5). Expressing *03, *05, or *06 slightly augmented EBV infectivity compared with vector control, although the difference was not statistically significant (Figure 5). Thus, the preference for gp42 binding to DQβ1 *02/*02 directly correlated with a similar preference for EBV infectivity in vitro. This finding provides further support for the observation that HLA class II, an EBV coreceptor, influences the rate of EBV seropositivity.

The difference in DQβ1 *0201– and *0301–mediated gp42 binding efficiency may be related to a polymorphism between the β1 alleles that involve the gp42 interaction interface. To further explore a mechanism for the association between HLA-DQ alleles and gp42 binding and EBV infectivity, we used the I-TASSER server (29) to predict the structures of DQβ1 *0201 and *0301. These 2 proteins share 92% identity at the amino acid level. To determine if polymorphic regions in DQβ1 *0201 and *0301 are located at the interface between gp42 and the DQβ1 proteins, we aligned the predicted DQβ1 structures with the β chain in the crystal structure of gp42 bound to HLA-DR1 (13) (PDB ID: 1KG0). Two amino acids at positions 77 and 78 in the DQβ1 proteins were found to be polymorphic at the interface (Figure 6). DQβ1 *0201 has glycine and glutamine at these positions, respectively, while *0301 has glutamine and valine. Therefore, the polymorphism in the region may contribute to the disparity in gp42 binding capacity.

Type 1 and type 2 EBV gp42 bind to HLA-DQ with similar efficiency; however, a neutralizing monoclonal antibody against gp42 blocks type 1 binding more efficiently than type 2. Two EBV types circulate in most populations: type 1 and type 2. Type 1 EBV is predominantly prevalent in the developed world, whereas type 2 EBV is present in people in equatorial Africa and New Guinea (3). Type 1 gp42 and type 2
gp42 share 98% amino acid identity. All 5 amino acids that differ between type 1 and type 2 gp42 are located in the C-type lectin domain of gp42 that is important for HLA class II interaction (13, 30). To identify if any of the polymorphic regions are located near the HLA-DQ–binding interface, we used the I-TASSER server (29) to predict the structure of type 2 gp42. For this analysis we used the crystal structure of type 1 gp42 bound to HLA-DR1 (13) (PDB ID: 1KG0) as a template. The predicted structure identified a polymorphic region between types 1 and 2 gp42 near the HLA-DQ–binding interface (Figure 7). Therefore, we determined if there was a difference between the 2 types of gp42 in HLA binding. Using human LCLs and transfected mouse cells that express HLA-DQ in the absence of HLA-DR or -DP, we found that types 1 and 2 EBV gp42 bound to HLA class II in a similar manner (Figure 8). A monoclonal antibody against gp42, F-2-1, potently blocks EBV infection of B cells but not epithelial cells (7, 8). Since epithelial cells usually do not express significant amounts of HLA class II, we postulated that the F-2-1 epitope might be located at the interface where gp42 and HLA class II

Figure 3. Lymphoblastoid cell lines expressing DQ*02/*02 bind more dimerized gp42 than cells expressing DQ*03/*03 or *04/*05 alleles. Cells were incubated with purified gp42-Fc as described in the legend to Figure 2 for gp42-His protein. Human TruStain FcX Fc receptor blocking solution (Biolegend) was then added to the cells for 5 minutes before adding anti–human IgG Alexa488 antibody, and gp42 binding was quantified by FACS. The cells were also incubated with IgG-Fc and binding of Ig-Fc was measured. The net mean fluorescence intensity of gp42-Fc binding was calculated by subtracting the background binding from IgG-Fc. The data were derived from 10 independent experiments. Means (short horizontal lines) ± SEM (long horizontal lines) are shown.

Table 5. HLA class II genotypes of lymphoblastoid cell lines used in EBV gp42 protein-binding assays

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>DQα1*</th>
<th>DQβ1*</th>
<th>DPα1*</th>
<th>DPβ1*</th>
<th>DRβ1*</th>
<th>DRβ3*</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHW09086</td>
<td>*05:01:01</td>
<td>*02:01</td>
<td>*02:01</td>
<td>*01:01</td>
<td>*04:01</td>
<td>*03:01</td>
</tr>
<tr>
<td>IHW09035</td>
<td>*05:01:01</td>
<td>*03:01:01</td>
<td>*05:01:01</td>
<td>*04:01</td>
<td>*11:01</td>
<td>*02:02:01</td>
</tr>
<tr>
<td>IHW01021</td>
<td>*04:01</td>
<td>*01:01</td>
<td>*04:02</td>
<td>*05:01:01</td>
<td>*01:03</td>
<td>*04:01:01</td>
</tr>
<tr>
<td>IHW01019</td>
<td>*04:01</td>
<td>*01:01</td>
<td>*04:02</td>
<td>*05:01:01</td>
<td>*01:03</td>
<td>*04:01:01</td>
</tr>
</tbody>
</table>
To test this possibility, we performed gp42 binding assays using human LCLs in the presence of F-2-1 or isotype control antibody. Monoclonal antibody F-2-1 blocked about 80% of type 1 EBV gp42 binding to HLA class II DQβ1*0201 and 85% of type 1 gp42 binding to DQβ1*0301 (Figure 9A). However, F-2-1 blocked only about 35% of type 2 gp42 binding to DQβ1*0201 and 50% binding to DQβ1*0301 (Figure 9B) (P < 0.001 for type 1 vs. type 2 gp42 binding). These results suggest that although the polymorphism in type 2 gp42 still allows efficient HLA class II binding, the interaction interface might be partially excluded from the F-2-1 blocking epitope.

Figure 4. Cells expressing HLA-DQβ1*02/*02 bind more gp42 than cells expressing DQ*03/*03 or *06/*06 when expressed independently of other HLA molecules. Mouse 3T3 cells expressing HLA-DQ αβ heterodimers were incubated with purified gp42-His followed by anti-His antibody as described in the legend to Figure 2. The amount of gp42 bound was quantified by FACS. Cell surface HLA-DQ β1 levels were also quantified in the same experiment by staining with Ia3 antibody followed by isotype-specific secondary antibody (Alexa647). The ratio of the mean fluorescence intensity (MFI) for gp42 binding (FL-4) divided by ΔMHC, which is the ratio of cell surface DQ expression to internal control GFP (24), is shown. The results were the same when we defined gp42 binding efficiency as the ratio of the MFI of gp42 binding divided by the MFI of HLA-DQ. The data were obtained from 10 independent experiments. Means (short horizontal lines) ± SEM (long horizontal lines) are shown.

Table 6. Stability of HLA-DQ on mouse 3T3 cells expressing DQ αβ heterodimers measured by ΔMHC^ and normalized against α1 *01:01/β1 *06:02

<table>
<thead>
<tr>
<th>ΔMHC</th>
<th>DQ β1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>*02:01</td>
</tr>
<tr>
<td>Raw</td>
<td>Normalized</td>
</tr>
<tr>
<td>α1 *01:01</td>
<td>0.0032</td>
</tr>
<tr>
<td>DQ α1</td>
<td>0.0455</td>
</tr>
<tr>
<td>α5:01</td>
<td>0.0104</td>
</tr>
</tbody>
</table>

^ΔMHC was calculated as a ratio of cell surface DQ expression level to the internal control GFP of the cell population.

interact. To test this possibility, we performed gp42 binding assays using human LCLs in the presence of F-2-1 or isotype control antibody. Monoclonal antibody F-2-1 blocked about 80% of type 1 EBV gp42 binding to HLA class II DQβ1*0201 and 85% of type 1 gp42 binding to DQβ1*0301 (Figure 9A). However, F-2-1 blocked only about 35% of type 2 gp42 binding to DQβ1*0201 and 50% binding to DQβ1*0301 (Figure 9B) (P < 0.001 for type 1 vs. type 2 gp42 binding). These results suggest that although the polymorphism in type 2 gp42 still allows efficient HLA class II binding, the interaction interface might be partially excluded from the F-2-1 blocking epitope.
**Discussion**

While EBV is one of the most ubiquitous viruses in the human population, about 5% of adults worldwide are not infected with EBV. A number of factors may be responsible for resistance to infection, including socioeconomic factors that may affect exposure to the virus and genetics of the individual (18–21). In this study, we compared a cohort of 106 EBV-seronegative and 218-seropositive blood donors screened from ~3,300 individuals and found that persons who were positive for HLA-DQβ1 *04/*05 or -DQβ1 *06/*06 were more likely to be EBV seronegative compared with other DQβ1 combinations, while those who were positive for DQβ1 *02/*02 were more likely to be EBV seropositive. However, with 15 different possible combinations of DQβ1 genotypes and a relatively small sample size due to the low rate of EBV seronegativity in adults, it is not surprising that while initial *P* values indicated significant associations between EBV serostatus and certain HLA-DQβ1 alleles, after adjusting for multiple comparisons the associations did not remain significant. While this is the largest study thus far testing HLA associations with EBV infectivity in seronegative persons, our results indicate the need for an even bigger sample size, since HLA-DQ is highly polymorphic and allele frequencies vary in the general population. Although the blood donor studies did not reach statistical significance, the results are supported by our in vitro experiments showing that EBV gp42 bound weakly to cells expressing HLA-DQ β1 *04/*05 and *06/*06, compared with cells expressing DQ β1 *02/*02. While EBV proteins interact with hundreds of

---

**Table 7. Significance of different HLA-DQ β1 alleles in binding to EBV gp42**

<table>
<thead>
<tr>
<th><em>P</em> value</th>
<th>DQβ1*</th>
<th>*03</th>
<th>*04</th>
<th>*05</th>
<th>*06</th>
</tr>
</thead>
<tbody>
<tr>
<td>*02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Data derived from 8 independent experiments shown in Figure 4.
host cell proteins, which may contribute to virus infectivity at various steps including virus entry, replication, and immune control (3, 31, 32), the observation that the interaction of gp42 with HLA class II is essential for EBV infection (7, 9, 12, 33) may explain the ability of a single genetic locus to influence infectivity with EBV.

Other much smaller studies have looked for associations between MHC class II alleles with EBV infectivity in seronegative persons. Jabs et al. reported a significant association between EBV seronegativity and HLA-DR 13 in a cohort of 20 EBV-seronegative and 32 EBV-seropositive healthy donors (34). Since HLA-DR 13 is genetically linked to HLA-DQ6 (DQβ1 *06), especially in populations of European descent (35), it is possible that DQβ1 *06 might have contributed to EBV seronegativity as an HLA-DRβ1*13-DQβ1 *06 haplotype in their cohort. In a study of 106 pediatric allograft recipients, Hocker and colleagues identified HLA-DR7 as an independent risk factor for EBV infection (36). Since HLA-DR7 is genetically associated with DQβ1 *02/*02, these results are consistent with our observation of a higher than expected proportion of HLA-DQβ1 *02 subjects that are seropositive.

MHC class I alleles have also been shown to correlate with EBV infectivity in small studies. Durovic et al. showed that EBV seronegativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants in a cohort of 17 EBV-seronegative and 39 EBV-seropositive subjects (37). Edmonds and colleagues found that HLA A10, A29, and B15 were underrepresented in a cohort of 27 EBV-seronegative persons when compared with 95 seropositive persons (38). Boyer et al. studied 55 EBV-seronegative and 367 EBV-seropositive persons and found an association of a blank HLA A locus with EBV seronegativity (39).

Previous studies have shown that in addition to binding HLA-DQ, gp42 also binds to DR and DP (9, 12). Therefore, DR and DP are also likely to be important in mediating EBV infection. Certain combinations of DQ, DR, and DP alleles may allow a small fraction of the general population to be refractory to infection by EBV. The HLA class II locus has at least 4,000 alleles with tens of thousands of possible combinations (IPD-
Figure 8. Type 1 and type 2 EBV gp42 bind to HLA-DQ with similar efficiency. Mouse 3T3 cells expressing HLA-DQ αβ heterodimers were incubated with the same amount of purified type 1 (top) or type 2 (bottom) gp42-His protein followed by anti-His antibody staining and detection of gp42 by FACS as described in the legend to Figure 4. MFI, mean fluorescence intensity; ΔMHC, the ratio of cell surface DQ expression to internal control GFP (24). The data were obtained from 5 independent experiments. Means (short horizontal lines) ± SEM (long horizontal lines) are shown.

IMGT/HLA database: https://www.ebi.ac.uk/ipd/imgt/hla) (40); therefore, it is virtually impossible to dissect the roles of DQ, DR, and DP together. Accordingly, we focused our study on DQ alleles without including the role of DR and DP. Haan and Longnecker expressed HLA-DQ heterodimer α1*03:01/β1*02:01 and α1*05:01/β1*03:03:02 in human LCLs that do not express endogenous HLA-DR, -DP, or -DQ. Using recombinant EBV that encodes GFP, they showed that expression of DQ β1 *02:01 increased EBV infectivity by 20-fold or more, while expression of B1*03:03 did not increase EBV infectivity (17). Additional studies by these authors showed that EBV gp42 interacts with the N-terminal region of DQ β1 (13, 23). We expanded these observations by expressing DQ β1 *04, *05 and *06, in addition to *02 and *03. Our findings that DQ β1 *02 not only bound significantly more gp42 than DQ β1 *03 or other alleles in human cells, but also facilitated significantly more infection, are consistent with the previous findings. This provides a mechanism that may explain the observation that a higher than expected proportion of EBV seropositive individuals have HLA-DQ β1 *02 alleles.

The evolution of diversity of HLA molecules is thought to be the result of selection and adaptation from combating infection (16). Paradoxically, EBV has adapted to use MHC class II molecules as entry coreceptors through its interaction with gp42. This interaction is essential for EBV infection (33). Although gp42 binding to HLA involves only the β chain outside the peptide groove of the αβ heterodimer (9, 10, 13), gp42 binding also interferes with the interaction of HLA-DR with the T cell receptor, inhibits generation of cytotoxic T cells, and impairs antigen presentation (9, 14, 15). Therefore, gp42 may have evolved multiple functions so that while it is essential for EBV infection, it may inhibit the cellular immune response to the virus.

Methods

Sample collection and EBV serology testing. Sera from about 3,300 healthy blood donors were collected over a 15-year period in the United States and Switzerland. Blood was obtained from blood donors at the Warren G. Magnuson Clinical Center at the NIH (~2,400 individuals), the Research Donor Program at the Frederick National Laboratory for Cancer Research (392 donors), and the Blood Transfusion Center in Basel, Switzerland (515 donors; see ref. 37). Sera were tested for IgG antibodies to the EBV viral capsid antigen using Captia Epstein-Barr Viral Capsid Antigen IgG ELISA kits following the manufacturer’s instructions (Trinity Biotech USA Inc.) or by multiplex microparticle technology (Luminex 200 Technology, Luminex Corp.) (37). All EBV-negative samples were then tested independently again at the NIH Department of Laboratory Medicine by a technician who was blinded to the prior results to confirm that each of these individuals was EBV seronegative.

Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat preparations of human blood using Ficoll-Paque Plus (GE Healthcare BioSciences). LCLs were established by infecting PBMCs with EBV B95.8 and propagated as described below.

Cells and reagents. LCLs were obtained from the International Histocompatibility Working Group (Fred Hutchinson Cancer Research Center) and maintained in RPMI 1640 medium with 15% FBS. Mouse 3T3 cells were grown in Dulbecco’s Modified Eagle Medium with 10% FBS. Anti-CD21 (R&D Systems, catalog MAB4909), mouse anti-His (GE Healthcare Life Sciences, catalog 27-4710-01), rabbit anti-His (Cell Signaling Technology, catalog 2365), and anti-HLA-DQ (MP Biomedicals, clone Ia3, catalog 68571) were used to stain cells. Secondary antibodies (anti-mouse IgG-Alexa488, catalog A11001; anti–mouse IgG2a-Alexa647, catalog 40716; anti–rabbit IgG-Alexa488, catalog A11034; and anti–human IgG-Alexa488 catalog A11013) were all purchased from Life Technologies. Human TruStain FcX Fc receptor blocking solution (catalog 422301) was obtained from Biolegend. F-2-1 antibody against EBV gp42 was previously described (7).

Generation of gp42-Fc, and type 1 and type 2 gp42-His proteins. gp42-Fc fusion protein (type 1) was made by transfecting CV1/EBNA1 cells with plasmid pDC409-BZLF2 purified with a protein A affinity column as described previously (9). Soluble gp42-His (type 1) was produced by PCR amplification of codon-optimized BZLF2 (the gene that encodes EBV gp42) from EBV strain B95.8 using a forward primer encoding a His-tag...
Figure 9. A neutralizing monoclonal antibody against gp42 blocks type 1 gp42 binding more efficiently than type 2 gp42 binding to human cells expressing different HLA class II alleles. Type 1 (top) or type 2 (bottom) gp42 proteins were preincubated with monoclonal anti-gp42 Ab, F-2-1, or a control antibody at room temperature for 30 minutes, and added to human lymphoblastoid cell lines and binding was assayed as described in the legend to Figure 2 except that detection of His-tagged gp42 was performed using rabbit anti-His antibody (Cell Signaling Technology) followed by Alexa488-conjugated...
anti-rabbit secondary antibody. The relative percentage of gp42 binding to cells in the presence of F-2-1 antibody was calculated against that of the control antibody, which was set at 100%. The relative binding of gp42 in the presence of F-2-1 antibody is shown. MFI, mean fluorescence intensity. The data were derived from 6 independent experiments. Means (short horizontal lines) ± SEM (long horizontal lines) are shown.

Genomic DNA extraction. Genomic DNA was extracted from PBMCs or blood clots using DNeasy Blood & Tissue Kits (Qiagen) following the manufacturer’s instructions. For DNA extraction from blood clots, the samples were first homogenized in 5 ml ACK lysis buffer (Lonza) and digested with proteinase K at 56°C overnight before using the DNeasy Blood & Tissue Kit.

HLA typing. Intermediate/high-resolution typing for HLA class II loci was performed using LABType sequence-specific oligonucleotide (SSO) Typing Kits obtained from One Lambda, Inc. LABType uses the reverse SSO DNA typing method with Luminex 200 Technology. First, target DNA was amplified by PCR using a group-specific primer. The PCR product was biotinylated during the amplification process, which allows it to be detected using R-phycoerythrin-conjugated streptavidin (SAPE). Some samples required the use of sequence-based typing (SBT) in order to verify or further identify the HLA type to a high-resolution level. SBT was performed utilizing a big dye terminator chemistry method. The primary PCR amplification reaction produced a 1.5-kb amplicon. Reagents for primary amplification and sequencing were obtained from HLAn Sequence-Based Typing Kits (Life Technologies). The primary-amplification PCR products were purified from excess primers, dNTPs, and genomic DNA using ExoSAP-IT (American Life Science). Each template was sequenced in the forward and reverse sequence orientation. Excess dye terminators were removed from the sequencing products using ethanol precipitation. The reaction products were reconstituted with 15 μl of Hi-DiTM Formamide (PE Applied Biosystems) and analyzed on an Applied Biosystems (ABI) Prism* 3730xL DNA Analyzer.

Generation of mouse cell lines stably expressing human HLA-DQ alleles. Stable cell lines expressing HLA-DQ alleles were generated as previously described (24). Briefly, recombinant retroviruses encoding various DQ α1 and β1 alleles were generated by transfecting expression plasmids (in a pMXs-IG backbone) into Plat-E packaging cells (Cell Biolabs). Mouse 3T3 cells were then transduced with the resulting pMXs-IG-DQ β1 retroviruses encoding different β1 alleles and a puromycin-resistance gene. Stably transduced cells were subsequently transduced with pMXs-IG-DQ α1 retroviruses carrying different HLA-DQ α1 genes and a GFP gene. FACS was carried out to enrich the GFP-positive cell population.

Generation and expression of HLA DQ plasmids for expression in human cells. DQ α1 chain *01:01:01, *04:01:01, and *05:01:01, and DQ β1 chain *02:01:01, *03:01:01, *04:02:01, *05:01:01:01, and *06:02:01 (dbMHC database, NCBI) were subcloned into pcDNA3.1. The resulting plasmids were verified by sequencing and transfected into LCL 721.174 cells by nucleofection using a Nucleofector with Kit V (Lonza, catalog VCA-1003).

EBV infection and detection. 293-EBV, a recombinant EBV encoding a hygromycin-resistance gene, was prepared as previously described (27). Cells infected with 293-EBV were harvested and total RNA was extracted using an RNeasy Plus Kit (Qiagen). To eliminate DNA contamination, the RNA was applied to a column that removes DNA and also treated with DNaseI (Roche) at 1.0 U/ml at room temperature for 15 minutes and repurified. Quantitative real-time RT-PCR was performed using the One-step RT-PCR Master mix (Promega) with a 7500 Real-Time PCR machine. Primers (5'-CTATCGAGCTTGGTGGACGG-3' and 5'-CTTCTACACAGCCCATCGT-3') and a FAM-labeled probe (5'-ACACAAATCGCCCGACAGAAGGCGAGC-3') for detection of the hygromycin-resistance gene product were synthesized by Integrated DNA Technologies. Primers and a VIC-labeled probe set detecting GAPDH was purchased from Applied Biosystems. Serial dilutions of plasmid carrying the hygromycin-resistance gene or GAPDH were used to generate standard curves.
Molecular modeling. The structures of DQ\(\beta\)1 *0201 and *0301 and gp42 were predicted using I-TASSER (29). The correctness of the modeled structure was evaluated by a confidence score (C-score) (43). C-scores are normally in the range of \([-5,2]\). A higher C-score indicates more confidence in the model, with a cutoff C-score greater than \(-1.5\) indicating models with a very high likelihood of correct topology (43). C-scores of the 5 best models of DQ\(\beta\)1 *0201 ranged from \([-3.22,-1.05]\), with a score of \(-1.05\) for the top model. All 5 models had similar folds, including in the interface regions, and differed only in the unstructured region in the C-terminus between residues 186 and 261. C-scores of the 5 best models of DQ\(\beta\)1 *0301 ranged from \([-3.35,-1.09]\), with a score of \(-1.09\) for the top model. All 5 models of DQ\(\beta\)1 *0301 had similar folds as well, including in the interface regions, and differed only in the unstructured regions in the N-terminus between residues 1 and 35 and in the C-terminus between residues 223 and 261. The top model for gp42 had a C-score of 1.18, while the other models had a score of \(-5\). Only the top predicted models were used for further structural analysis.

Statistics. All statistical analysis was done in R (44). To compare EBV-seropositive with EBV-seronegative subjects by HLA type, we used Fisher’s exact tests to compare individual HLA-DQ\(\beta\)1 types with all other HLA-DQ\(\beta\)1 types for the odds of being EBV seropositive. The odds ratio of being EBV seropositive was defined as being greater than 1, while the odds ratio of being seropositive was defined as less than 1. Individual HLA-DQ\(\beta\)1 \(P\) values were adjusted to reduce the false discovery rate (45). Because experiments run on the same day were likely correlated, Wilcoxon signed-rank tests (46) were used to compare the binding activity of gp42 in cell lines that differed by HLA-DQ\(\beta\)1. The false discovery rate was controlled by \(P\)-value adjustment within each independent experiment. Comparison between type 1 and 2 in the presence of F-2-1 over 6 different experiments on different days was performed using a linear mixed-effects model including a random intercept of experiment and adjusting for HLA-DQ\(\beta\)1 type with the R packages lme4 (*) and lmerTest (**). To compare EBV infection between the HLA-DQ\(\beta\)1 types, the Wilcoxon signed-rank test (46) was used with pairing by experimental day over 6 independent experiments. A \(P\) value less than 0.05 was considered significant.

Study approval. The local Institutional Biosafety Committees approved blood donations at the NIH in Bethesda, Maryland, the Research Donor Program at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, and the Blood Transfusion Center in Basel, Switzerland, and written consent was obtained from the volunteers before blood donations.

Author contributions
QL, WB, FA, WH, YH, and RLH performed the research. EG did statistical analysis. HM provided critical reagents and advice. CH provided clinical specimens. AR performed molecular modeling. QL and JIC designed the experiments, analyzed the data, and wrote the paper.

Acknowledgments
We thank Melanie Spriggs for plasmid pDC409-BZLF2 and Sharon Adams for assistance with HLA typing. We thank Toshio Kitamura for providing pMXs plasmids and Henri-Jacques Delecluse and Bill Suden for the cell line expressing 293-EBV. This work was supported by the intramural research program of the National Institute of Allergy and Infectious Diseases. This project has been funded in whole or in part with federal funds from the National Cancer Institute, NIH, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Address correspondence to: Jeffrey I. Cohen, Building 50, Room 6134, 50 South Drive, MSC8007, NIH, Bethesda, Maryland 20892-8007, USA. Phone: 301.496.5265; E-mail: jcohen@niaid.nih.gov.


